New map4k1 inhibitors

Abstract

The present invention covers MAP4K1 inhibitor compounds of formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for treatment, amelioration or prevention of neoplastic or abnormal cell proliferative disorders, such as cancer, conditions with dysregulated immune response, other disorders associated with aberrant Map4K1 signaling, or amelioration of vaccine therapies or cell therapies, as a sole agent or in combination with other active ingredients.